Furthermore, in PIK3CA-mutant HNSCC cells, a combination of a PI3K/mTORi and palbociclib was reported to be effective in xenograft tumors (38), albeit by a poorly understood mechanism. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.